Clinical trial · Interventional
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
An Open-Label, Randomized Phase IB/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Why stopped (as posted): The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carfilzomib | Drug | Carfilzomib | ALIAS |
| Daratumumab | Drug | Daratumumab | ALIAS |
| Forimtamig | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (9)
- type
- EXPERIMENTAL
- label
- Dose Exploration Phase: Forimtamig (Dose 1) + Carfilzomib
- description
- Participants will receive Dose 1 of forimtamig, subcutaneous (SC) injection in combination with carfilzomib, intravenous (IV) infusion until disease progression.
- interventionNames
- Drug: Forimtamig
- Drug: Carfilzomib
- type
- EXPERIMENTAL
- label
- Dose Exploration Phase: Forimtamig (Dose 2) + Carfilzomib
- description
- Participants will receive Dose 2 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
- interventionNames
- Drug: Forimtamig
- Drug: Carfilzomib
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Documented diagnosis of MM according to the IMWG diagnostic criteria * Evidence of progressive disease based on Investigator's determination of response by IMWG criteria on or after last dosing regimen * Measurable disease * AEs from prior anti-cancer therapy resolved to Grade ≤ 1, * Adequate organ functions Exclusion Criteria: * Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the last dose of study drug * Plasma cell leukemia with circulating plasma cell count ≥ 5% or \>500/microliter (µL) * Participants with known amyloidosis * Participants with myelodysplastic syndrome * Prior treatment with monoclonal antibody (mAb) and antibody-drug conjugate within 4 weeks or 5 half-lives of the drug, whichever is shorter * Prior anti-cancer therapy (chemotherapy, small molecule/tyrosine kinase inhibitors, radiotherapy) within 14 days prior to first forimtamig administration * Prior solid organ transplantation * Active auto-immune disease or flare within 6 months prior to start of study treatment * Known or suspected chronic active Epstein-Barr virus (EBV) infection * Hepatitis B virus (HBV) infection * Acute or chronic hepatitis C virus (HCV) infection * Known history of HIV seropositivity * Live vaccine(s) within one month prior to start of the treatment * Participants not fully vaccinated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as per local recommendations * Previous refractoriness to carfilzomib * Participants who discontinued prior carfilzomib treatment due to treatment-related toxicity * Participants with known liver cirrhosis * Participants eligible for allogeneic stem cell transplantation (SCT) or autologous SCT at the time of enrollment for Study BP43437 are excluded
References
Publications (0)
Data not yet available